Bruker Cellular Analysis, Inc.
DelistedCIK 1689657fmd_114C91XGN0D53ASX4CWGFVG15AManufacturing · Laboratory Analytical InstrumentsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2023, 19 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Total revenues | 31 | 57 | 64 | 85 | 79 |
| Cost of revenue | 8 | 13 | 20 | 29 | 25 |
| Gross profit | 23 | 43 | 45 | 57 | 54 |
| Research and development | 29 | 38 | 47 | 59 | 53 |
| Selling, general and administrative | 15 | 22 | 38 | 69 | 95 |
| Total operating expenses | 44 | 60 | 85 | 127 | 152 |
| Operating income | (21) | (17) | (40) | (71) | (98) |
| Interest expense | 2 | 1 | 1 | 1 | 1 |
| Other non-operating income (expense) | (1) | (1) | 0 | 0 | (0) |
| Income before taxes | (23) | (18) | (41) | (72) | (98) |
| Income tax expense | 0 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | (23) | (18) | (42) | (72) | (98) |
| Net income | (23) | (18) | (42) | (72) | (98) |
| Net income to common shareholders | (27) | (22) | (43) | (72) | (98) |